Bens A, et al. - Considering the laboratory studies suggesting inhibition of breast cancer development is related to the inhibition of the cyclooxygenase (COX)-2 enzymes, researchers assessed the impact of post-diagnosis use of COX-2 selective or other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of contralateral breast cancer (CBC) among Danish breast cancer patients. For this purpose, they analyzed 52,723 women diagnosed with breast cancer, identified using the clinical database of the Danish Breast Cancer Group, between 1996 and 2012. Findings reveal that the risk of CBC does not decrease with non-aspirin NSAID use, irrespective of the COX-2 selectivity.